Iskanje po repozitoriju

A+ | A- | | SLO | ENG

Povzetek: Introduction: COVID-19 has profoundly affected people's physical and mental health. Nurses, a crucial part of the healthcare workforce, face considerable anxiety due to the risk of infection. The aim of this study was to examine the relationship between COVID-19 fear levels among infected and non-infected nurses and to identify the influencing factors.Methods: For this cross-sectional study, data were collected through an online survey from 20 to 27 December 2020. A total of 281 nurses in Turkey participated, of whom 95 were COVID-19-positive and 186 were COVID-negative. Data were collected using the Fear of COVID-19 Scale. Descriptive statistics, Kolmogorov-Smirnov test, one-way ANOVA, Mann-Whitney U, and Kruskal-Wallis tests were used. Statistical significance was set at p < 0.05.Results: The sample consisted of 58.9% women and 41.1% men. Of the participants who tested positive, 42.1% had cared for COVID-19 patients on the night shift, compared to 35.5% of those who tested negative. Both groups reported using inadequate protective equipment. COVID-19-positive nurses reported an anxiety score of 22.89 (s = 8.97), while COVID-19-negative nurses reported an anxiety score of 21.10 (s = 7.11).Discussion and conclusion: Higher anxiety levels were observed among nurses who tested positive for COVID-19. These results emphasise the need for more support and resources for nurses. It is important to address nurses' anxiety and take appropriate measures, including reasonable shift schedules and psychological support.
Ključne besede: SARS Coronavirus 2 infection, perception, anxiety, nursing, quantitative study
Objavljeno v DiRROS: 28.01.2026; Ogledov: 143; Prenosov: 53
Povezava na datoteko
Gradivo ima več datotek! Več...

Povzetek: Hudi akutni respiratorni sindrom (SARS) je nova, huda in lahko prenosljiva infekcijska bolezen. Prvič so jo prepoznali februarja 2003, v nekaj mesecih se je s Kitajske razširila v 29 držav. SARS povzroča nov virus (koronavirus SARS-CoV), proti kateremu človek ni imun, zato lahko okuži vsakega izmed nas. S človeka na človeka se prenaša pretežno kapljično, redkeje po zraku (aerogeno) ali preko kontaminiranih površin, morda tudi z blatom in urinom. Bolezen se prične od 2 do 10 dni po okužbi z vročino, mišičnimi bolečinami in glavobolom. Začetnim simptomom sledijo kašelj, dihalna stiska in driska. Več kot 20% bolnikov potrebuje zdravljenje na intenzivnem oddelku z intubacijo in mehanskim predihavanjem. Med dosedanjimi obolelimi je bilo več kot polovico zdravstvenih delavcev, v večini primerov je prišlo do prenosa okužbe v bolnišnici. Širjenje okužbe lahko preprečimo z zgodnjim odkrivanjem novih primerov, izolacijo,ustrezno zaščito zdravstvenih delavcev ter nadzorom oseb, ki so bile v stiku z bolnikom s SARS. V članku so predstavljeni bolezenski znaki, povzročitelj, načini prenosa in higienski ukrepi za preprečevanje širjenja SARS.
Ključne besede: infekcijske bolezni, SARS, pljučnica virusna, koronavirus, bolezenski znaki, povzročitelj, načini prenosa, 21 st., zdravstveni delavci
Objavljeno v DiRROS: 28.01.2026; Ogledov: 139; Prenosov: 0

Povzetek: Coronavirus disease-2019 (COVID-19) has become a global pandemic, necessitating the development of new medicines. In this investigation, we identified potential natural flavonoids and compared their inhibitory activity against spike glycoprotein, which is a target of SARS-CoV-2 and SARS-CoV. The target site for the interaction of new inhibitors for the treatment of SARS-CoV-2 has 82% sequence identity and the remaining 18% dissimilarities in RBD S1-subunit, S2-subunit, and 2.5% others. Molecular docking was employed to analyse the various binding processes used by each ligand in a library of 85 natural flavonoids that act as anti-viral medications and FDA authorised treatments for COVID-19. In the binding pocket of the target active site, remdesivir has less binding interaction than pectolinarin, according to the docking analysis. Pectolinarin is a natural flavonoid isolated from Cirsiumsetidensas that has anti-cancer, vasorelaxant, anti-inflammatory, hepatoprotective, anti-diabetic, anti-microbial, and anti-oxidant properties. The S-glycoprotein RBD region (330–583) is inhibited by kaempferol, rhoifolin, and herbacetin, but the S2 subunit (686–1270) is inhibited by pectolinarin, morin, and remdesivir. MD simulation analysis of S-glycoprotein of SARS-CoV-2 with pectolinarin complex at 100ns based on high dock-score. Finally, ADMET analysis was used to validate the proposed compounds with the highest binding energy.
Ključne besede: coronaviruses, SARS-CoV-2, S-glycoproteins, computational analysis
Objavljeno v DiRROS: 16.12.2025; Ogledov: 695; Prenosov: 137
Celotno besedilo (5,57 MB)
Gradivo ima več datotek! Več...

Povzetek: Introduction: The classification of antiphospholipid syndrome (APS) comprises clinical criteria (vascular thrombosis or obstetric complications throughout life) and laboratory criteria (antiphospholipid antibodies (aPLs) positivity, confirmed at least twice at 12-week interval). Methods: In 100 patients admitted to the hospital with COVID-19 pneumonia, thrombosis and pregnancy complications were recorded during the hospital stay and in personal medical history. They were tested for nine types of aPLs at four time points (admission, deterioration, discharge, and 3-month follow-up): anticardiolipin (aCL), anti-β2-glycoproteinI (anti-β2GPI), and antiphosphatidylserine/prothrombin (aPS/PT) isotypes IgM/IgG/IgA. Results: During hospitalization, aPLs were detected at least once in 51% of patients. All 7% of deceased patients tested negative for aPLs upon admission, and only one patient became aCL IgG positive as his condition worsened. In 83.3% of patients, intrahospital thrombosis was not related to aPLs. One patient with pulmonary artery and cerebral artery thrombosis was given an APS diagnosis (triple aPLs positivity on admission, double on follow-up). Personal anamnesis (PA) for thromboembolism was verified in 10 patients, all of whom tested negative for aPLs at admission; however, transition to aPLs positivity at discharge (as the disease subsided) was seen in 60% of patients: three of six with arterial thrombosis (at follow-up, two did not appear, and one was negativized) and three of four with deep vein thrombosis (one was confirmed at follow-up and diagnosed with APS, one was negativized, and one did not appear). At admission, the majority of the aPLs were of the aCL IgG class (58.8%). Unexpectedly, as the COVID-19 disease decreased, anti-β2GPI IgG antibodies (linked with thromboses) became newly positive at discharge (14.9%), as confirmed at follow-up (20.8%). Conclusion: The incidence of APS in our cohort was 2.0%, whereas in the general population, it ranges from 0.001% to 0.002%. The incidence might have increased even more if the four aPLs-positive patients with intrahospital thrombosis/history of thrombosis had attended follow-up. Recommendation: All patients with severe COVID-19 or post-COVID syndrome should be evaluated for current/previous thrombosis and tested for aPLs at least twice: at admission to the hospital and at discharge, then retested 3 months later in positive cases in order to be given the appropriate therapy.
Ključne besede: COVID-19, SARS-CoV2, anti-phosphatidylserine-prothrombin (aPS/PT) antibodies, anti-β2-glycoprotein I (anti-β2GPI) antibodies, anticardiolipin (aCL) antibodies, antiphospholipid antibodies (aPLs), antiphospholipid syndrome, immunology, post-COVID syndrome, vascular thrombosis
Objavljeno v DiRROS: 01.12.2025; Ogledov: 332; Prenosov: 127
Celotno besedilo (1,28 MB)
Gradivo ima več datotek! Več...

Povzetek: The SARS-CoV-2 envelope protein (2-EPRO), a viroporin crucial for viral pathogenesis, is a promising target for antiviral drug development as it is highly conserved and functionally important. Although it is a promising therapeutic target for the treatment of COVID-19, it has often been overlooked in previous studies. In this study, a high-throughput virtual screening of nearly one billion compounds was performed, followed by rigorous filtering and re-docking. Eight best-scoring and chemically versatile lead candidates were identified. In molecular dynamics simulations, three of these ligands showed stable protein-ligand complexes occupying the 2-EPRO channel pore. Among these, ZINC001799167680 (L3) and ZINC001081252239 (L2) exhibited the strongest binding a˙inity, with key interactions at residues ASN15, THR11 and GLU8 identified by Molecular Mechanics Poisson-Boltzmann Surface Area analysis. All ligands were compared with the known inhibitor rimantadine and showed stronger binding to the protein. These in silico results highlight the potential of focusing on the 2-EPRO ion channel in the development of novel COVID-19 therapeutics and pave the way for further in vitro and in vivo studies.
Ključne besede: SARS-CoV-2 envelope protein, viroporin, ion channel, channel blockers, molecular dynamics simulations, free energy calculations, drug discovery
Objavljeno v DiRROS: 05.09.2025; Ogledov: 452; Prenosov: 195
Celotno besedilo (1,82 MB)
Gradivo ima več datotek! Več...